Isotechnika's Lead Immunosuppressive Drug, ISA247 Positioned to Enter Phase II/III Clinical Trials for Uveitis by its Partner Lux Biosciences

Edmonton, Canada, November 28 (ots/PRNewswire) - Isotechnika Inc.
(TSX:ISA) today announced that its lead immunosuppressive drug,
ISA247 is positioned to enter Phase II/ III human clinical trials in
uveitis by its partner Lux Biosciences, following interactions with
the Food and Drug Administration and clearance of its
Investigational New Drug Application (IND).

On May 25 of this year, Isotechnika signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
exclusive, worldwide rights to develop and commercialize
Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of
all ophthalmic diseases.

ISA247, which is referred to as LX211 by Lux, will be investigated
in the oral capsule formulation for the treatment of active and
control of quiescent non-infectious uveitis in three separate
pivotal protocols. Interested parties are encouraged to visit
www.clinicaltrials.gov or contact Lux Biosciences for further
information on the trial designs.

"We're very pleased that we've succeeded in moving this project
along according to plan," commented Ulrich Grau, President & CEO of
Lux Biosciences. "With preparations well under way, we look forward
to enrolling our first patient into the pivotal studies by early
January of next year. We believe that our next generation
calcineurin inhibitor LX211 has great potential in uveitis; a
well-studied and approved medication other than steroids would be
enormously beneficial for patients who suffer from this debilitating
disease."

Dr. Randall Yatscoff, Isotechnika's President & CEO stated,
"Having ISA247 enter into pivotal trials for its third indication,
uveitis, speaks to the versatility of the drug to potentially treat a
number of immune-based health ailments. We are extremely pleased that
our partner Lux Biosciences has been able to move this indication
forward at such an aggressive pace." Dr. Yatscoff further stated,
"We remain committed to advancing ISA247 in multiple indications to
increase shareholder value and provide more effective treatments to
kidney transplant patients and to those who suffer from psoriasis and
uveitis."

About Uveitis

Uveitis is an autoimmune disease resulting in chronic inflammation
of the eye. Uveitis can be classified according to its location:
anterior uveitis occurs in the front of the eye, intermediate
uveitis occurs in the middle section of the eye, and posterior
uveitis occurs at the back of the eye. Inflammation of all three
locations is termed panuveitis. There is substantial evidence
indicating the involvement of T-lymphocytes, key cells involved in
inflammatory processes, in the development of uveitis.

Uveitis is an under-diagnosed and under-recognized medical
condition that causes vision impairment, ocular pain, and loss of
vision. Experts estimate that 10% of new cases of blindness in the
U.S. are caused by this disease. Approximately 300,000 people suffer
from uveitis in the U.S. alone, the majority of who are affected by
anterior uveitis. The only therapeutic class approved by the FDA for
treatment of uveitis is corticosteroids, which are burdened with
multiple side effects, such as hypertension, hyperglycemia, and
hypercholesterolemia.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a
Canadian Phase III human clinical trial for the treatment of moderate
to severe psoriasis. ISA247 is currently being investigated in a
North American Phase IIb human clinical trial for the prevention of
kidney graft rejection. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which
successfully completed Phase I clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.

About Lux Biosciences Inc.

Founded in 2005, Lux Biosciences is a privately held biotechnology
company dedicated to the identification, optimization, development
and commercialization of products for the treatment of ophthalmic
diseases. The company has assembled a portfolio of product candidates
based on compounds with demonstrated utility in non-ophthalmic
indications that offer potential to address major market
opportunities in the ophthalmic field. ISA247, or LX211 as it is
known by Lux, is the most advanced of these and is expected to enter
pivotal clinical trials for the treatment of uveitis by early 2007
and additionally offers a pipeline of other potential product
applications. More information on Lux Biosciences can be found at
www.luxbio.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

www.isotechnika.com

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext. 246, Fax:
+1-780-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-909-4661, Fax: +1-780-484-4105,E-mail:
sgillis-paulgaard@isotechnika.com; Lux Biosciences Contacts:
UlrichGrau, Ph.D., Lux Biosciences, Phone: +1-917-518-2875, E-mail:
ulrich.grau@luxbio.com; Paul Kidwell, Suda Communications (media),
Phone: +1-617-296-3854, E-mail: paulkidwell@comcast.net